Prognosis of single tooth implants following alveolar ridge preservation with two recombinant human bone morphogenetic protein-2 delivery systems by Baek, Hyeong-Jin et al.
Baek et al. BMC Oral Health          (2021) 21:201  
https://doi.org/10.1186/s12903-021-01565-5
RESEARCH
Prognosis of single tooth implants 
following alveolar ridge preservation with two 
recombinant human bone morphogenetic 
protein-2 delivery systems
Hyeong‑Jin Baek1†, Il‑hyung Kim1,2†, Pil‑Young Yun1 and Young‑Kyun Kim1,3* 
Abstract 
Background:   We previously reported similar efficacies of alveolar ridge preservation (ARP) on single extraction 
socket with two different E. coli derived recombinant human bone morphogenetic protein‑2 (rhBMP‑2) delivery 
systems (Cowell BMP, Cowell medi Co, Busan, Korea; β‑tricalcium phosphate and hydroxyapatite particle & O‑BMP, 
Osstem Implant Co, Busan, Korea; absorbable collagen sponge). After the trial, we completed implant therapy and 
observed over an average of 3 years. This follow‑up study was performed retrospectively to compare result of implant 
treatment at the preserved alveolar ridge site.
Methods:   Patients who underwent extraction of single tooth and received ARP with one of two rhBMP‑2 delivery 
systems from October 2015 to October 2016 were enrolled. Twenty‑eight patients (Group 1: Cowell BMP 14; Group 2: 
O‑BMP 14) who underwent implant therapy and prosthetic treatment were included in study. Stability and marginal 
bone loss (MBL) of each implant were collected from medical charts and radiographs, and analyzed. The survival and 
success rates of implants were calculated.
Results: The primary implant stability represented by implant stability quotient (ISQ) for Groups 1 and 2 was 69.71 
and 72.86, respectively. The secondary implant stability for Groups 1 and 2 was 78.86 and 81.64, respectively. Primary 
and secondary stabilities were not statistically different (P = 0.316 and 0.185, respectively). MBL at the latest follow‑up 
was 0.014 mm in Group 1 over 33.76 ± 14.31 months and 0.021 mm in Group 2 over 40.20 ± 9.64 months, with no sig‑
nificant difference (P = 0.670). In addition, the success rate of implants was 100% (14/14) in Group 1 and 92.9% (13/14) 
in Group 2, with survival rate of 100% (14/14) in Group 1 and 92.9% (13/14) in Group 2.
Conclusions: We confirmed good prognosis in both groups as a result of implant therapy after ARP with each of two 
rhBMP‑2 carriers.
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Background
Maintenance and preservation of alveolar width and 
height are important for proper dental implant place-
ment. However, it is difficult to place implants in areas of 
previous tooth extraction since alveolar bone is prone to 
horizontal and vertical absorption [1, 2]. Therefore, sev-
eral procedures including ridge preservation have been 
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introduced to maintain the volume and shape of alveo-
lar bone after tooth extraction, but the effectiveness of 
these procedures remains controversial [2, 3]. The use of 
autogenous bone for alveolar augmentation and preser-
vation has been considered the gold standard [4]. How-
ever, complications including donor site comorbidity, 
limited amount of harvest, resorption after grafting, and 
difficulty in harvesting because of anatomical and under-
lying diseases make difficulties to use autogenous bone 
[3, 4]. So, bone substitutes including allogenic, xeno-
genic, and alloplastic materials have been used as alterna-
tives to autogenous bone graft, but each has limitations 
as well [5–9]. As a result, osteoinductive materials have 
been considered and used for prevention of alveolar bone 
resorption. Among them, recombinant human bone 
morphogenetic protein-2 (rhBMP-2) has been author-
ized to be used for alveolar ridge and maxillary sinus aug-
mentation in the maxillofacial area [10]. Several studies 
have shown that bone grafting with rhBMP-2 at alveolar 
bone defect sites resulted in clinically and histologically 
similar volume and quality of alveolar bone compared 
to outcomes of grafting with autogenous bone [11–13]. 
Therefore, it is believed that rhBMP-2 is an appropriate 
material for post-extraction alveolar bone preservation 
[14]. However, it is necessary to identify proper carriers 
of rhBMP-2 for optimal bone regeneration through oste-
oinductivity since rhBMP-2 tends to be absorbed when 
used alone [15–17].
We previously compared the efficacy of two rhBMP-2 
delivery systems (Cowell BMP, Cowell medi Co, Busan, 
Korea & O-BMP, Osstem Implant Co, Busan, Korea) on 
alveolar bone preservation. And we concluded from the 
12-week clinical trial that the β-tricalcium phosphate 
and hydroxyapatite particle delivery system with E. coli-
derived rhBMP-2 (Cowell BMP) and newly developed 
absorbable collagen sponge delivery system with E. coli 
derived rhBMP-2 (O-BMP) showed similar efficiency for 
the alveolar ridge preservation (ARP). [18].
This retrospective follow-up study was conducted to 
compare the outcomes of implant therapy at the pre-
served alveolar bone sites.
Methods
  This study was performed in accordance with the Hel-
sinki guidelines and was approved by the Institutional 
Review Board at Seoul National University Bundang 
Hospital (B-2010-645-103). Patients who underwent sin-
gle-tooth extraction and ARP with one of two rhBMP-2 
delivery systems from October 29th, 2015 to October 
6th, 2016 were chosen. Informed consent was obtained 
from all subjects. Among them, 28 patients whose medi-
cal records indicates implant therapy and prosthetic 
treatment at a preserved alveolar bone site were selected, 
with 14 patient in each group (Group 1: Cowell BMP; 
Group 2: O-BMP).
Patient demographics, treated site, characteristics of 
the implant fixture, implant treatment procedures, pri-
mary and secondary stability values, and amount of 
alveolar bone loss were collected using medical chart and 
radiographs (periapical view). If additional surgeries were 
performed at the time of implant placement, the type of 
and reason for surgery were noted.
The stability of each implant was measured as implant 
stability quotient (ISQ) according to an Osstell Mentor 
(Osstell AB, Gothenburg, Sweden). Primary stability was 
measured immediately after implant placement, and sec-
ondary stability was measured at the time of the second 
surgery or during the impression for the prosthesis.
To determine the amount of marginal bone loss (MBL), 
radiographic analyses were performed. For measuring it, 
intraoral periapical radiographs produced with the paral-
leling technique on a digital intraoral radiographic device 
(Heliodent Sirona, Sirona Dental Systems Inc., NY, USA) 
and measurement system (PACS, INFINIT Co., Seoul, 
Korea) were used. MBL was defined as the mean differ-
ences of the shortest vertical distances from the mesial 
and distal aspect of implant shoulder to the implant-
bone contact points on the aspect measured between the 
radiographs taken immediately after functional loading, 1 
year after loading, and final observation that exceeded 1 
year after loading (Fig. 1).
Implant success was evaluated with the criteria sug-
gested by Zarb and Albrektsson in 1998. If one implant 
did not satisfy the criteria, the case was regarded as a 
failure. The time point at which the failure occurred was 
set as the final follow-up of that implant. Survival was 
defined as normal functioning of the prosthesis with no 
symptoms, such as mobility and patient discomfort [19].
The interval from ARP to implant placement was 
defined as the alveolar bone remodeling period, and that 
to commencement of function was defined as the total 
treatment period. The interval from implant placement 
to impression acquisition was defined as the healing 
period, and that to the most recent follow-up was defined 
as the observation period.
Differences between groups were analyzed using t-test. 
If the variables did not follow a normal distribution, the 
Mann–Whitney test was used. Statistical significance 
was noted a level of 95% (SPSS Ver. 25.0, SPSS Korea 
Institute, Inc., Seoul, Korea).
Results
Group 1 contained 8 males and 6 females with a mean age 
of 59.14 ± 13.39 (38–79) years. Group 2 contained 6 males 
and 8 females with a mean age of 59.14 ± 10.77 (30–70) 
years. The surfaces of all implants were sandblasted, large 
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grit, acid-etched (SLA). The distribution of implant types 
was 8 and 6 Dentium implants (Suwon, Korea), 5 and 2 
Neobiotech implants (Busan, Korea), and 1 and 6 Osstem 
implants (Busan, Korea) in Groups 1 and 2, respectively. 
The mean diameter and length of the implant fixtures 
were 4.89 ± 0.40 (4.5−6.0) mm and 9.21 ± 1.64 (7.0−1.5) 
mm in Group 1, respectively, and 4.86 ± 0.50 (4.0–6.0) 
mm and 9.43 ± 1.16 (7.0–10.0) mm in Group 2. There 
were no statistical differences in diameter and length of 
the implants (P = 0.836 and 0.693, respectively) (Table 1).
Nine implants were placed in the maxilla and 5 
implants were placed in the mandible in Group 1. In 
Group 2, 10 implants were placed in the maxilla and 4 
implants were placed in the mandible. A total of 11 addi-
tional surgeries was performed during implant instal-
lation. Six sinus augmentation surgeries and 1 guided 
bone regeneration (GBR) procedure were completed for 
bone height compensation in Group 1. Of the 4 GBR pro-
cedures conducted in Group 2, half were conducted for 
bone height and other the half for bone width compensa-
tion (Table 2).
Primary stability (ISQ) was 69.71 ± 6.01 and 
72.86 ± 9.81 for Groups 1 and 2, respectively, and sec-
ondary stability (ISQ) was 78.86 ± 5.49 and 81.64 ± 5.34, 
neither of which was statistically different (P = 0.316 and 
0.185, respectively) (Table 3).
The alveolar bone remodeling period was 8.11 ± 8.92 
months in Group 1 and 3.83 ± 1.13 months in Group 2 
(Mann–Whitney test, P = 0.210). The mean total treat-
ment period was 14.56 ± 9.03 months for Group 1 and 
9.45 ± 2.56 months for Group 2 (P = 0.052). The mean 
healing period was 5.65 ± 1.66 and 4.91 ± 1.88 months 
for Groups 1 and 2 (P = 0.286), respectively. The aver-
age observation period after implant placement was 
33.76 ± 14.31 months in Group 1 and 40.20 ± 9.64 
months in Group 2 (Mann–Whitney test, P = 0.329). 
MBL was 0.013 ± 0.039 mm and 0.001 ± 0.022 mm 
for Groups 1 and 2, respectively, at 1 year after loading 
(P = 0.551), and no implant showed annual vertical bone 
loss greater than 0.2 mm. MBL was 0.014 ± 0.039 mm 
in Group 1 and 0.021 ± 0.056 mm in Group 2 at the last 
follow-up (P = 0.670) (Table 4).
The success rate was 100% (14/14) in Group 1 and 
92.9% (13/14) in Group 2. Only one implant in Group 2 
was removed, at 31.31 months after functioning due to 
progressive alveolar bone loss and subsequent mobil-
ity due to peri-implantitis. The survival rate was 100% 
(14/14) in Group 1 and 92.9% (13/14) in Group 2.
Discussion
Many studies have reported the efficacy of horizontal 
and vertical bone volume preservation of ARP after tooth 
extraction [19–26]. This type of study would be meaning-
ful because it shows the prognosis of implant treatment 
after alveolar ridge preservation and compares the long-
term efficacy of two graft materials for alveolar ridge 
preservation.
The ISQ quantifies implant stability as a value from 1 
to 100; a value less than 45 means implant failure, while a 
value between 60 and 70 indicates success of the implant 
[27]. Nedir et al. suggested that implants with an ISQ of 
47 or higher should be considered stable [28]. Balleri et al. 
noted that successful osseointegration can be expected 
if the ISQ value immediately after implant placement 
is between 57 and 82 [29]. In the present study, the ISQ 
measured immediately after implant placement was 69.71 
in Group 1 and 72.86 in Group 2. This suggests good-
quality alveolar bone through the previous ARP, allowing 
excellent initial stability. At approximately 5 months after 
implantation, ISQ increased by 9.15 and 8.87 on average 
Fig. 1 Periapical radiographs of a dental implant. a Immediately after loading; b 1 year after loading; c most recently
Table 1 Diameter and length of implants
The comparison between groups was performed with Student’s t test
  Group 1   Group 2   t   P
Diameter (mm) 4.89 ± 0.40 4.86 ± 0.50 0.21 0.84
Length 9.21 ± 1.64 9.43 ± 1.16 − 0.4 0.69
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for Groups 1 and 2, respectively. Therefore, demonstrat-
ing excellent osseointegration.
The success rate of single-tooth implants varies accord-
ing to placement protocol. Success rates of single-tooth 
implants over 1–2 years are reported as 66.7–92.0% for 
immediate placement after extraction and 83.3–100% 
for placement at 3–5 months after extraction [30–32]. 
In the present study, success rates of 100% in Group 1 
and 92.9% in Group 2 were observed over an average of 
3 years. Of all 28 implants in the two groups, 27 satisfied 
the success criterion, resulting in an overall success rate 
of 96.43%. Except for 1 implant that was removed at 31 
months after functioning, 27 implants survived until the 
final follow-up date without mobility, progressive bone 
loss, or patient discomfort. This can be interpreted as a 
high level of positive treatment outcome in both groups.
Since there was no significant difference in groups 
for MBL, success rate, or survival rate, we propose that 
Table 2 Diameter and length of implants and combined surgery at the time of placement
SA, sinus augmentation; GBR, guided bone regeneration
Group No. Site Implant fixture (mm) Combined surgery
  Diameter   Length   Type   
Compensation
1 1 #17 5 10 SA Bone height
2 #25 4.5 11.5 – –
3 #16 5 8.5 SA Bone height
4 #36 5 7 – –
5 #15 4.5 12 – –
6 #26 4.5 8.5 SA Bone height
7 #16 5 11.5 SA Bone height
8 #36 4.5 10 – –
9 #16 5 8.5 SA Bone height
10 #47 5 8 – –
11 #36 6 8 GBR Bone height
12 #36 5 7 – –
13 #16 5 8.5 SA Bone height
14 #17 4.5 10 – –
2 1 #16 5 10 – –
2 #27 5 10 – –
3 #16 4.5 10 – –
4 #17 5 10 – –
5 #46 5 10 – –
6 #47 5 7 GBR Bone height
7 #46 6 10 GBR Bone width
8 #16 5 10 – –
9 #17 5 10 – –
10 #11 4 10 – –
11 #15 4.5 10 – –
12 #11 4 10 GBR Bone width
13 #27 5 8 – –
14 #46 5 7 GBR Bone height
Table 3 Primary and secondary stability of placed implants
ISQ, Implant Stability Quotient
The comparison between groups was performed with Student’s t test
Group 1 Group 2 T P
ISQ
 Primary 69.71 ± 6.01 72.86 ± 9.81 − 1.022 0.316
 Secondary 78.86 ± 5.49 81.64 ± 5.34 − 1.361 0.185
Table 4 Marginal bone loss after 1 year of function and most 
recent follow ups
MBL, Marginal Bone Loss
The comparison between groups was performed with Mann–Whitney test
Group 1 Group 2 t P
MBL (mm)
 1 year of function 0.013 ± 0.039 0.001 ± 0.022 0.604 0.551
 Most recent 0.014 ± 0.039 0.021 ± 0.056 − 0.431 0.670
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adequate-quality alveolar bone was formed with implant 
treatment after ARP with the two rhBMP-2 delivery 
systems. These results can be seen as continuation and 
extension of our previous study showing well-preserved 
extraction sockets in both groups after ARP. The change 
of alveolar height and width at the level of the alveo-
lar crest at 12 weeks after ARP with Cowell BMP and 
O-BMP were − 0.68 ± 1.42 mm and − 0.26 ± 2.58 mm, 
respectively [18]. However, 6 of 14 sites in Group 1 had 
bone height deficiency, and 2 each of 14 sites in Group 2 
showed lack of bone height and bone width, at the time of 
implant placement, requiring additional surgery. Despite 
the need for additional surgery, all of the surgeries actu-
ally performed were minimally invasive procedures such 
as maxillary sinus augmentation using crestal approach 
or GBR with a small amount of bone substitutes. Taken 
together, the results indicate that ARP with each of two 
rhBMP-2 delivery systems can reduce invasiveness in 
later implant surgery. In addition, previous ARP could 
diminish the necessity of additional subsequent bone 
grafting in the cases of large alveolar bone defects that 
could not adequately have restored the bone volume with 
ARP alone.
One limitation of this study is that we used implants 
from three companies. However, all the implants used 
in this study were surface-treated with SLA, bone level 
implant with internal connections, and possessed the 
same taper type. In addition, even though we used CBCT 
for evaluation of changes of alveolar bone in our previ-
ous study, use of periapical radiographs for this analysis 
in the present study is another limitation.
Conclusions
The outcome of implant treatment after ARP with each 
of two different rhBMP-2 delivery systems was favora-
ble. Therefore, we suggest that ARP using either of these 
systems is appropriate pre-treatment for later implant 
therapy.
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